Tricentis Acquisition Extends Selenium and Appium Test Automation in the Cloud
8.8.2019 13:00:00 EEST | Business Wire | Press release
Tricentis announced that it has acquired TestProject, a first-of-its-kind community-powered test automation platform designed for Agile teams. As part of its commitment to TestProject, Tricentis will be investing in research and development to advance the product, extend the community, and help testers master best practices for web, Android, and iOS test automation.
TestProject is built on the leading open source test automation tools: Selenium and Appium. It supports all major operating systems, and enables any software team to test web, Android, and iOS apps using a “low-code/no-code” approach. With the community-driven approach, automation building blocks are shared with the entire community—reducing the time required to construct robust test automation. AI-based matching automatically analyzes the application under test and recommends addons that will enhance the tests.
“Tricentis is a company that has always placed the tester first,” said Sandeep Johri, CEO of Tricentis. “By joining forces with TestProject, we strengthen our commitment to democratizing test automation, providing an open platform for innovation. Working with enterprises, we’ve witnessed a distinct need to scale open source testing frameworks across the enterprise. TestProject, with its cloud-based, community-driven technology, delivers a scalable and collaborative solution.”
TestProject will retain its free, community-based offering and will operate independently, providing an open platform for all testers in all industries. Testers can continue using the programming languages, tools, and operating systems of their choice for their projects. Moreover, TestProject users can enhance their test automation with additional Tricentis capabilities for Agile test management, load testing, and end-to-end testing. Tricentis will leverage its partnerships with leading cloud providers like Microsoft and AWS to extend its current lead in cloud testing.
TestProject’s current CEO, Mark Kardashov, will become Managing Director of TestProject and the TestProject team will continue driving TestProject’s innovation within Tricentis.
“I’m extremely proud of what TestProject and our community have accomplished over the past several years, and I can’t wait to see what lies ahead,” Kardashov said. “Testing is a critical piece of any software development pipeline, and I’m thrilled to be joining forces with the market leader, Tricentis, to ensure every tester is empowered. Tricentis’ focus on the tester aligns perfectly with our own, and Tricentis’ scale, tools, and global brand will play a huge role in making TestProject the leader in community-powered test automation.”
About TestProject
TestProject is the world’s first cloud-based, community testing platform. TestProject makes it easier for testers to do their jobs quickly, and to collaborate using popular open source frameworks (e.g., Selenium and Appium) to ensure quality with speed. By fostering a collaborative community that can come together — as individuals and in teams — TestProject is shaping the future of software testing. Founded in 2015, TestProject is headquartered in Petah-Tikva, Israel. Learn more at https://testproject.io.
About Tricentis
With the industry's #1 Continuous Testing platform, Tricentis is recognized for reinventing software testing for DevOps. Through agile test management and advanced test automation optimized to support over 150+ technologies, we provide automated insight into the business risks of your software releases--transforming testing from a roadblock to a catalyst for innovation. The result is accelerated software delivery speed, improved cost efficiency, and reduced business risk.
Tricentis is the only vendor to achieve "leader" status in all three top analyst reports (i.e., the "Triple Crown.") This honor is based on our technical leadership, innovation, and a Global 2000 customer base of 1500+ companies, including global enterprises such as Allianz, ANZ Bank, Cisco, Dolby, Experian, First Data, HSBC, Merck, Office Depot, Samsung, Swiss Re, Starbucks, Telstra, UBS, Vodafone, Whole Foods, and WorldPay. Customers rely on Tricentis to achieve and sustain test automation rates of over 90 percent--increasing risk coverage while accelerating testing to keep pace with Agile and DevOps.
Tricentis has a global presence in Austria, Australia, Belgium, Denmark, Germany, India, Netherlands, Singapore, Switzerland, Poland, United States and the UK. To learn more, visit https://www.tricentis.com or follow us on LinkedIn, Twitter, and Facebook .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190808005170/en/
Contact information
Wayne Ariola
w.ariola@tricentis.com
(650) 393-3054
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom